Oxbryta® (voxelotor)
Sickle Cell Disease
ApprovedSupported late-stage development & NDA
Key Facts
Indication
Sickle Cell Disease
Phase
Approved
Status
Supported late-stage development & NDA
Company
About Cleo Life Sciences
Founded in 2004, Cleo Life Sciences offers a unique hybrid model combining strategic CMC consulting with hands-on, small-scale laboratory prototyping to de-risk and accelerate pharmaceutical development. The company leverages its founder's deep industry experience, having contributed to the CMC development of five commercial drugs and over 60 clinical-stage candidates. Its mission is to transform pharmaceutical development by enabling earlier, faster, and more efficient product and process development for its biopharma clients.
View full company profileOther Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Research |
| CT-101 | Cetya Therapeutics | Pre-clinical |
| Endari (L-glutamine oral powder) | Emmaus Life Sciences | Approved |
| Undisclosed | Biossil | Phase 2/3 |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Digital Model for Sickle Cell Disease | Koneksa Health | Development/Validation |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| CLY-124 | Cellarity | Phase 1 |
| AB1 | AkiraBio | Pre-clinical |
| Oral Decitabine/Tetrahydrouridine | Novo Nordisk | Phase 2 |